TMA

While instrument placements in the quarter increased to 41 from 36 a year ago, the firm missed the consensus analysts' estimate on the top and bottom lines. 

Unhappy with the sales of its urine-based molecular test for the prostate cancer biomarker PCA3, Canadian cancer diagnostics firm DiagnoCure is urging Hologic, the test's commercial conduit, to either step up commercialization efforts or relinquish rights to the test back to Diag

Hologic said this week that fiscal first-quarter clinical diagnostics revenues from Gen-Probe, acquired last summer, were up 9 percent over the comparable period last year, but that blood screening revenues contributed by Gen-Probe declined slightly year over year.

Hologic's planned $3.7 billion acquisition of Gen-Probe, announced earlier this week, is expected to create the largest diagnostics company focused on women's health, according to Hologic officials.

According to a recent survey conducted by investment bank Jeffries, US molecular diagnostics labs expressed "stronger than expected" interest in Gen-Probe's recently launched assays for trichomonas and human papillomavirus, as well as "notable enthusiasm" for the upcoming launch of the company's

Roka Bioscience said Friday that it has secured $47.5 million in Series D financing to support the commercialization of its molecular food safety testing platform.

The 2009 Gen-Probe spinoff has exclusive licensing rights to various Gen-Probe nucleic acid-based tests and instrumentation for use in industrial applications.

Nucleic acid testing of blood donations using Gen-Probe's and Novartis' Procleix Ultrio assay revealed a higher-than-expected rate of HBV infection in blood donors, including those who had been previously vaccinated and who would not have been identified by routine antibody screening, according to the study.

The new platform, called Panther, is expected to help Gen-Probe capture market share in the area of molecular testing at mid- and low-volume clinical laboratories, clinics, and physicians' offices as it competes with platforms from companies such as Roche, Qiagen, Cepheid, and Becton Dickinson.

Pages

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.